CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anesiva, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anesiva, Inc.
650 Gateway Boulevard
Phone: (650) 624-9600p:650 624-9600 South San Francisco, CA  94304  United States Ticker: ANSVQANSVQ

This company is no longer actively traded on any major stock exchange.

Business Summary
Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management. Its portfolio includes two products. Adlea, a long-acting, site-specific, non-opioid analgesic, is being developed for moderate to severe pain, and has completed multiple Phase II trials in post-surgical, musculoskeletal and neuropathic pain and Phase III trials in bunionectomy and total knee arthroplasty (TKA, or total knee replacement surgery). The Company is initially pursuing an indication for Adlea for the management of acute pain associated with orthopedic surgeries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system, was approved by the Food and Drug Administration (FDA) in August 2007, to reduce the pain associated with peripheral intravenous (IV) insertions or blood draws in children 3 to 18 years of age. Zingo was approved in January 2009, to reduce the pain associated with blood draws in adults.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200912/31/2008YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director Michael L.Kranda 55 6/16/2008 6/16/2008
Vice President - Finance, Chief Accounting Officer John H.Tran 34 5/1/2008 2/18/2008
Director Daniel S.Janney 44 2/9/2008 2/9/2008
3 additional Officers and Directors records available in full report.

Business Names
Business Name
AlgoRx Pharmaceuticals, Inc.
Anesiva Hong Kong Limited
ANSVQ

General Information
Number of Employees: 16 (As of 1/10/2009)
Outstanding Shares: 40,465,030 (As of 10/30/2009)
Shareholders: 165
Stock Exchange: OTC
Federal Tax Id: 770503399
Fax Number: (302) 674-5266


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023